[SCHEDULE 13G/A] Beta Bionics, Inc. Amended Passive Investment Disclosure
Rhea-AI Filing Summary
Beta Bionics Inc ownership disclosure: The Vanguard Group reports beneficial ownership of 0 shares of Common Stock, representing 0% of the class as of 03/13/2026.
The filing is an amendment (Schedule 13G/A) reflecting an internal realignment at The Vanguard Group and states certain subsidiaries will report separately in reliance on SEC Release No. 34-39538. The form is signed by Ashley Grim on 03/26/2026.
Positive
- None.
Negative
- None.
Insights
Filing shows no beneficial stake by The Vanguard Group in Beta Bionics.
The Schedule 13G/A amends prior reporting to state 0 shares owned and 0% ownership as of 03/13/2026. The filing attributes the change to an internal realignment and reliance on SEC Release No. 34-39538 for disaggregated reporting.
Cash-flow treatment or trading intent is not stated; subsequent filings from the reporting entities may disclose holdings if they report separately.
Amendment clarifies reporting structure under SEC guidance.
The text cites SEC Release No. 34-39538 and explains subsidiaries or business divisions will report beneficial ownership separately from The Vanguard Group, Inc. This explains the zero ownership entry rather than an explicit sale or acquisition.
Investors should note the filing is procedural: it documents reporting alignment changes and includes the preparer signature dated 03/26/2026.